Carmustine en es it fr

Carmustine Brand names, Carmustine Analogs

Carmustine Brand Names Mixture

  • No information avaliable

Carmustine Chemical_Formula


Carmustine RX_link

Carmustine fda sheet

Carmustine msds (material safety sheet)

Carmustine MSDS

Carmustine Synthesis Reference

Johnston TP et al. J Med Chem 122:669-681(1963).

Carmustine Molecular Weight

214.049 g/mol

Carmustine Melting Point

31 oC

Carmustine H2O Solubility

< 0.1 g/100 mL at 18 °C

Carmustine State


Carmustine LogP


Carmustine Dosage Forms

Powder for solution; Wafer

Carmustine Indication

For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.

Carmustine Pharmacology

Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.

Carmustine Absorption

5 to 28% bioavailability

Carmustine side effects and Toxicity

The oral LD50s in rat and mouse are 20 mg/kg and 45 mg/kg, respectively. Side effects include leukopenia, thrombocytopenia, nausea. Toxic effects include pulmonary fibrosis (20-0%) and bone marrow toxicity.

Carmustine Patient Information

No information avaliable

Carmustine Organisms Affected

Humans and other mammals